Japan Cancer Pain Management Market Forecast 2024-2032

List of Tables

KEY FINDINGS

The Japan cancer pain management market is expected to grow with a CAGR of 5.75% during the forecast period 2024-2032.

MARKET INSIGHTS

According to the National Institutes of Health study, Cancer Prevalence Projections in Japan and Decomposition Analysis of Changes in Cancer Burden, 2020-2050, cancer prevalence in Japan is expected to rise significantly by 2050. The total number of cancer cases is projected to reach 3,665,900, with a possible range from 3,210,200 to 4,201,400 cases, marking a 13.1% increase from 2020. A notable aspect of this increase is the gender disparity. Female cancer survivors are projected to increase by 27.6%, while male survivors will see a modest rise of only 0.8%. Consequently, from 2040 onward, the number of female cancer survivors will surpass that of males.

By 2050, colorectal, female breast, prostate, lung, and stomach cancers are anticipated to be the most prevalent cancer types, comprising 66.4% of all cancer survivors in Japan. For males, the cancers with the highest projected absolute increases in prevalence include prostate, lung, and malignant lymphoma. In contrast, for females, the most significant increases are expected in breast, colorectal, and corpus uteri cancers. This growing cancer prevalence underscores the need for effective cancer pain management solutions.

Japan has made significant strides in managing cancer-related pain, recognizing it as an essential part of comprehensive cancer care. To enhance cancer pain treatment for patients, the country has adopted various strategies, such as setting up palliative care units and incorporating pain management protocols within oncology departments.

Moving ahead, opioid analgesics are commonly used to manage moderate to severe cancer pain. Japan follows international guidelines for opioid use, ensuring that patients receive adequate pain relief while minimizing the risks of addiction and side effects. These guidelines for cancer pain medications are part of a broader strategy to manage pain effectively. Additionally, the Japanese healthcare system promotes multidisciplinary approaches involving oncologists, palliative care specialists, nurses, and pharmacists to provide holistic pain management.

SEGMENTATION ANALYSIS

The report on the Japan cancer pain management market includes the segmentation analysis based on drug type and disease indication.

Market by Drug Type:

Opioids
Morphine
Fentanyl
Other Morphines
Non-Opioids
Acetaminophen
Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
Nerve Blockers

Market by Disease Indication:

Lung Cancer
Colorectal Cancer
Breast Cancer
Prostate Cancer
Blood Cancer
Other Disease Indications

Inkwood Research's report on the Japan cancer pain management market provides in-depth insights as well as the market's segmentation analysis. The detailed evaluation of the market includes Competitive Landscape and Value Chain Analysis.

COMPETITIVE ANALYSIS

Key players operating in the Japan cancer pain management market include Daiichi Sankyo Company Ltd, Shionogi & Co Ltd, Hisamitsu Pharmaceutical Co Ltd, Pfizer, Teva Pharmaceutical Industries, Mundipharma International, etc.

Pfizer Inc is a biopharmaceutical firm that develops healthcare solutions ranging from disease prevention to the treatment of chronic ailments and rare disorders. The company's three main business segments are pharmaceuticals, vaccines, and consumer healthcare. Pfizer has a substantial presence in North America, Europe, Asia, Latin America, and other locations. Its global headquarters are in New York City, United States.

Product Code: 90649

1. RESEARCH SCOPE & METHODOLOGY

1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

2.1. MARKET SIZE & ESTIMATES
2.2. COUNTRY SNAPSHOT - JAPAN
2.3. COUNTRY ANALYSIS - JAPAN
2.4. SCOPE OF STUDY
2.5. CRISIS SCENARIO ANALYSIS
- 2.5.1. IMPACT OF COVID-19 ON THE JAPAN CANCER PAIN MANAGEMENT MARKET
2.6. MAJOR MARKET FINDINGS
- 2.6.1. INNOVATIONS IN PALLIATIVE CARE
- 2.6.2. SURGE IN PERSONALIZED MEDICINE APPROACHES
- 2.6.3. EXPANSION OF SPECIALIZED CANCER CARE FACILITIES

3. MARKET DYNAMICS

3.1. KEY DRIVERS
- 3.1.1. INCREASING PREVALENCE OF CANCER IN JAPAN
- 3.1.2. SURGE IN GERIATRIC POPULATION
- 3.1.3. CONTINUOUS EDUCATION AND KNOWLEDGE DISSEMINATION IN PAIN MANAGEMENT
3.2. KEY RESTRAINTS
- 3.2.1. REGULATORY CHALLENGES AND APPROVAL DELAYS
- 3.2.2. HIGH COST OF TREATMENT
- 3.2.3. OPIOID SIDE EFFECTS AND ADDICTION CONCERNS

4. KEY ANALYTICS

4.1. KEY MARKET TRENDS
- 4.1.1. ADVANCEMENTS IN MEDICAL TECHNOLOGY IN JAPAN
- 4.1.2. SUPPORTIVE GOVERNMENT POLICIES FOR CANCER PAIN MANAGEMENT
- 4.1.3. ACTIVE R&D BY PHARMACEUTICAL COMPANIES
4.2. PESTLE ANALYSIS
- 4.2.1. POLITICAL
- 4.2.2. ECONOMICAL
- 4.2.3. SOCIAL
- 4.2.4. TECHNOLOGICAL
- 4.2.5. LEGAL
- 4.2.6. ENVIRONMENTAL
4.3. PORTER'S FIVE FORCES ANALYSIS
- 4.3.1. BUYERS POWER
- 4.3.2. SUPPLIERS POWER
- 4.3.3. SUBSTITUTIONS
- 4.3.4. NEW ENTRANTS
- 4.3.5. INDUSTRY RIVALRY
4.4. GROWTH PROSPECT MAPPING - JAPAN
4.5. VALUE CHAIN ANALYSIS
- 4.5.1. RESEARCH & DEVELOPMENT
- 4.5.2. REGULATORY APPROVAL
- 4.5.3. MANUFACTURING
- 4.5.4. DISTRIBUTION
- 4.5.5. END-USERS

5. MARKET BY DRUG TYPE

5.1. OPIOIDS
5.2. MORPHINE
- 5.2.1. FENTANYL
- 5.2.2. OTHER MORPHINES
5.3. NON-OPIOIDS
5.4. ACETAMINOPHEN
5.5. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
5.6. NERVE BLOCKERS

6. MARKET BY DISEASE INDICATION

6.1. LUNG CANCER
6.2. COLORECTAL CANCER
6.3. BREAST CANCER
6.4. PROSTATE CANCER
6.5. BLOOD CANCER
6.6. OTHER DISEASE INDICATIONS

7. COMPETITIVE LANDSCAPE

7.1. KEY STRATEGIC DEVELOPMENTS
- 7.1.1. MERGERS & ACQUISITIONS
- 7.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
- 7.1.3. PARTNERSHIPS & AGREEMENTS
- 7.1.4. BUSINESS EXPANSIONS & DIVESTITURES
7.2. COMPANY PROFILES
- 7.2.1. DAIICHI SANKYO COMPANY LIMITED
  - 7.2.1.1. COMPANY OVERVIEW
  - 7.2.1.2. PRODUCTS
  - 7.2.1.3. STRENGTHS & CHALLENGES
- 7.2.2. SHIONOGI & CO LTD
  - 7.2.2.1. COMPANY OVERVIEW
  - 7.2.2.2. PRODUCTS
  - 7.2.2.3. STRENGTHS & CHALLENGES
- 7.2.3. HISAMITSU PHARMACEUTICAL CO LTD
  - 7.2.3.1. COMPANY OVERVIEW
  - 7.2.3.2. PRODUCTS
  - 7.2.3.3. STRENGTHS & CHALLENGES
- 7.2.4. PFIZER
  - 7.2.4.1. COMPANY OVERVIEW
  - 7.2.4.2. PRODUCTS
  - 7.2.4.3. STRENGTHS & CHALLENGES
- 7.2.5. TEVA PHARMACEUTICAL INDUSTRIES
  - 7.2.5.1. COMPANY OVERVIEW
  - 7.2.5.2. PRODUCTS
  - 7.2.5.3. STRENGTHS & CHALLENGES
- 7.2.6. MUNDIPHARMA INTERNATIONAL
  - 7.2.6.1. COMPANY OVERVIEW
  - 7.2.6.2. PRODUCTS
  - 7.2.6.3. STRENGTHS & CHALLENGES